India Community Acquired Pneumonia Drugs Market - Industry Trends and Forecast to 2031

TABLE OF CONTENTS

1 INTRODUCTION 12

• 1.1 OBJECTIVES OF THE STUDY 12
• 1.2 MARKET DEFINITION 12
• 1.3 OVERVIEW OF THE INDIA COMMUNITY ACQUIRED PNEUMONIA DRUGS MARKET 12
• 1.4 CURRENCY AND PRICING 14
• 1.5 LIMITATIONS 14
• 1.6 MARKETS COVERED 14

2 MARKET SEGMENTATION 16

• 2.1 MARKETS COVERED 16
• 2.2 GEOGRAPHICAL SCOPE 17
• 2.3 YEARS CONSIDERED FOR THE STUDY 17
• 2.4 DBMR TRIPOD DATA VALIDATION MODEL 18
• 2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 21
• 2.6 MULTIVARIATE MODELLING 22
• 2.7 PRODUCT SEGMENT LIFELINE CURVE 22
• 2.8 MARKET END USER COVERAGE GRID 23
• 2.9 DBMR MARKET POSITION GRID 24
• 2.10 VENDOR SHARE ANALYSIS 25
• 2.11 SECONDARY SOURCES 26
• 2.12 ASSUMPTIONS 26

3 EXECUTIVE SUMMARY 27

4 PREMIUM INSIGHTS 30

• 4.1 PESTAL ANALYSIS 31
• 4.2 PORTERS FIVE FORCES 32

5 REGULATIONS 33

6 MARKET OVERVIEW 35

• 6.1 DRIVERS 37
  • 6.1.1 RISING PREVALENCE OF PNEUMONIA 37
  • 6.1.2 GROWING ANTIBIOTIC RESISTANCE PATHOGENS DRUGS 38
  • 6.1.3 INCREASING HEALTHCARE AWARENESS AND EXPENDITURE 38
  • 6.1.4 GROWING DEMAND FOR GENERIC AND LOCALLY PRODUCED DRUGS 39
• 6.2 RESTRAINTS 40
  • 6.2.1 AFFORDABILITY AND PRICE SENSITIVITY ASSOCIATED WITH THE DRUGS 40
  • 6.2.2 UNEQUAL DISTRIBUTION OF HEALTHCARE RESOURCES IN DIFFERENT LOCALITY 41
  • 6.2.3 PIPELINE OF NEW ANTIBIOTIC DEVELOPMENT 42
• 6.3 OPPURTUNITIES 42
  • 6.3.1 TECHNOLOGY-DRIVEN SOLUTIONS AND INNOVATION 42
  • 6.3.2 FOCUS ON AFFORDABILITY AND GENERICS OF THE PNEUMONIA DRUGS 43
  • 6.3.3 FOCUS ON LEVERAGING TELEMEDICINE AND SPECIFIC AGED PATIENT 44
• 6.4 CHALLENGES 45
  • 6.4.1 LIMITED HEALTHCARE INFRASTRUCTURE AND ACCESS 45
  • 6.4.2 ANTIBIOTIC RESISTANCE AND COUNTERFEITING IN PHARMACEUTICAL DRUGS 45

7 INDIA COMMUNITY ACQUIRED PNEUMONIA DRUGS MARKET, BY PRODUCT 46

• 7.1 OVERVIEW 47
• 7.2 MACROLIDES 50
  • 7.2.1 AZITHROMYCIN 50
  • 7.2.2 ERYTHROMYCIN 50
  • 7.2.3 CLARITHROMYCIN 51
  • 7.2.4 OTHERS 51
• 7.3 B-LACTAM ANTIBIOTICS 51
  • 7.3.1 CEPHALOSPORIN 52
    • 7.3.1.1 THIRD GENERATION CEPHALOSPORIN 52
    • 7.3.1.2 SECOND GENERATION CEPHALOSPORIN 52
    • 7.3.1.3 FOURTH GENERATION CEPHALOSPORIN 52
    • 7.3.1.4 FIRST GENERATION CEPHALOSPORIN 52
  • 7.3.2 AMOXICILLIN AND CLAVULANATE POTASSIUM 53
  • 7.3.3 PIPERACILLIN AND TAZOBACTAM 53
  • 7.3.4 AMPICILLIN AND SULBACTAM 53
  • 7.3.5 OTHERS 53
• 7.4 QUINOLONES 53
  • 7.4.1 MOXIFLOXACIN 54
  • 7.4.2 LEVOFLOXACIN 54
  • 7.4.3 GEMIFLOXACIN 54
  • 7.4.4 GATIFLOXACIN 54
  • 7.4.5 CIPROFLOXACIN 54
  • 7.4.6 DELAFLOXACIN 54
  • 7.4.7 OTHERS 54
• 7.5 TETRACYCLINE 55
  • 7.5.1 DOXYCYCLINE 55
  • 7.5.2 OMADACYCLINE 55
  • 7.5.3 OTHERS 55
• 7.6 CARBAPENEM 56
  • 7.6.1 IMIPENEM 56
  • 7.6.2 MEROPENEM 56
  • 7.6.3 ERTAPENEM 56
• 7.7 GLYCOPEPTIDE ANTIBIOTICS 57
  • 7.7.1 VANCOMYCIN 57
  • 7.7.2 TEICOPLANIN 57
  • 7.7.3 OTHERS 57
• 7.8 PLEUROMUTILIN 57
• 7.9 OTHERS 57

8 INDIA COMMUNITY ACQUIRED PNEUMONIA DRUGS MARKET, BY ROUTE OF ADMINISTRATION 58

• 8.1 OVERVIEW 59
• 8.2 ORAL 62
• 8.3 INTRAVENOUS 62

9 INDIA COMMUNITY ACQUIRED PNEUMONIA DRUGS MARKET, BY DOSAGE 63

• 9.1 OVERVIEW 64
• 9.2 TABLET 67
• 9.3 SOLUTION 67

10 INDIA COMMUNITY ACQUIRED PNEUMONIA DRUGS MARKET, BY PRODUCT TYPE 68

• 10.1 OVERVIEW 69
• 10.2 GENERICS 72
• 10.3 BRANDED 72

11 INDIA COMMUNITY ACQUIRED PNEUMONIA DRUGS MARKET, BY MODE OF PURCHASE 73

• 11.1 OVERVIEW 74
• 11.2 PRESCRIPTION 77
• 11.3 OTC 77

12 INDIA COMMUNITY ACQUIRED PNEUMONIA DRUGS MARKET, BY TYPE 78

• 12.1 OVERVIEW 79
• 12.2 BACTERIAL 82
• 12.3 VIRUS 82
• 12.4 FUNGI 82

13 INDIA COMMUNITY ACQUIRED PNEUMONIA DRUGS MARKET, BY POPULATION TYPE 83

• 13.1 OVERVIEW 84
• 13.2 CHILDREN 87
• 13.3 GERIATRICS 87
• 13.4 ADULTS 87

14 INDIA COMMUNITY ACQUIRED PNEUMONIA DRUGS MARKET, BY END USER 88

• 14.1 OVERVIEW 89
• 14.2 HOSPITALS 92
• 14.3 SPECIALTY CLINICS 92
• 14.4 HOME CARE 92
• 14.5 OTHERS 92

15 INDIA COMMUNITY ACQUIRED PNEUMONIA DRUGS MARKET, BY DISTRIBUTION CHANNEL 93

• 15.1 OVERVIEW 94
• 15.2 HOSPITAL PHARMACY 97
• 15.3 RETAIL PHARMACY 97
• 15.4 ONLINE PHARMACY 97
• 15.5 OTHERS 97

16 INDIA COMMUNITY ACQUIRED PNEUMONIA DRUGS MARKET, COMPANY LANDSCAPE 98

• 16.1 COMPANY SHARE ANALYSIS: INDIA 98

17 SWOT ANALYSIS 99

18 COMPANY PROFILES 100

• 18.1 PFIZER INC. 100
  • 18.1.1 COMPANY SNAPSHOT 100
  • 18.1.2 REVENUE ANALYSIS 101
  • 18.1.3 PRODUCT PORTFOLIO 101
  • 18.1.4 RECENT DEVELOPMENT 102
• 18.2 CIPLA INC. 103
  • 18.2.1 COMPANY SNAPSHOT 103
  • 18.2.2 REVENUE ANALYSIS 103
  • 18.2.3 PRODUCT PORTFOLIO 104
  • 18.2.4 RECENT DEVELOPMENT 104
• 18.3 ASTRAZENECA 105
  • 18.3.1 COMPANY SNAPSHOT 105
  • 18.3.2 REVENUE ANALYSIS 105
  • 18.3.3 PRODUCT PORTFOLIO 106
  • 18.3.4 RECENT DEVELOPMENT 106
• 18.4 ABBOTT 107
  • 18.4.1 COMPANY SNAPSHOT 107
  • 18.4.2 REVENUE ANALYSIS 107
  • 18.4.3 PRODUCT PORTFOLIO 108
  • 18.4.4 RECENT DEVELOPMENT 108
• 18.5 TEVA PHARMACEUTICAL INDUSTRIES LTD. 109
  • 18.5.1 COMPANY SNAPSHOT 109
  • 18.5.2 REVENUE ANALYSIS 109
  • 18.5.3 PRODUCT PORTFOLIO 110
  • 18.5.4 RECENT DEVELOPMENTS 110
• 18.6 AUROBINDO PHARMA USA 111
  • 18.6.1 COMPANY SNAPSHOT 111
  • 18.6.2 REVENUE ANALYSIS 111
  • 18.6.3 PRODUCT PORTFOLIO 112
  • 18.6.4 RECENT DEVELOPMENT 112
• 18.7 BAXTER 113
  • 18.7.1 COMPANY SNAPSHOT 113
  • 18.7.2 REVENUE ANALYSIS 113
  • 18.7.3 PRODUCT PORTFOLIO 114
  • 18.7.4 RECENT DEVELOPMENT 114
• 18.8 FRESENIUS KABI 115
  • 18.8.1 COMPANY SNAPSHOT 115
  • 18.8.2 REVENUE ANALYSIS 115
  • 18.8.3 PRODUCT PORTFOLIO 116
  • 18.8.4 RECENT DEVELOPMENT 116
• 18.9 NOVARTIS AG 117
  • 18.9.1 COMPANY SNAPSHOT 117
  • 18.9.2 REVENUE ANALYSIS 117
  • 18.9.3 PRODUCT PORTFOLIO 118
  • 18.9.4 RECENT DEVELOPMENT 118

19 QUESTIONNAIRE 119

20 RELATED REPORTS 123

LIST OF TABLES

• TABLE 1 INDIA COMMUNITY ACQUIRED PNEUMONIA DRUGS MARKET, BY PRODUCT, 2022-2031 (USD MILLION) 50
• TABLE 2 INDIA MACROLIDES IN COMMUNITY ACQUIRED PNEUMONIA DRUGS MARKET, BY TYPE, 2022-2031 (USD MILLION) 50
• TABLE 3 INDIA B-LACTAM ANTIBIOTICS IN COMMUNITY ACQUIRED PNEUMONIA DRUGS MARKET, BY TYPE, 2022-2031 (USD MILLION) 51
• TABLE 4 INDIA CEPHALOSPORIN IN COMMUNITY ACQUIRED PNEUMONIA DRUGS MARKET, BY TYPE, 2022-2031 (USD MILLION) 52
• TABLE 5 INDIA QUINOLONES IN COMMUNITY ACQUIRED PNEUMONIA DRUGS MARKET, BY TYPE, 2022-2031 (USD MILLION) 53
• TABLE 6 INDIA TETRACYCLINE IN COMMUNITY ACQUIRED PNEUMONIA DRUGS MARKET, BY TYPE, 2022-2031 (USD MILLION) 55
• TABLE 7 INDIA CARBAPENEM IN COMMUNITY ACQUIRED PNEUMONIA DRUGS MARKET, BY TYPE, 2022-2031 (USD MILLION) 56
• TABLE 8 INDIA GLYCOPEPTIDE ANTIBIOTICS IN COMMUNITY ACQUIRED PNEUMONIA DRUGS MARKET, BY TYPE, 2022-2031 (USD MILLION) 57
• TABLE 9 INDIA COMMUNITY ACQUIRED PNEUMONIA DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION) 62
• TABLE 10 INDIA COMMUNITY ACQUIRED PNEUMONIA DRUGS MARKET, BY DOSAGE, 2022-2031 (USD MILLION) 67
• TABLE 11 INDIA COMMUNITY ACQUIRED PNEUMONIA DRUGS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 72
• TABLE 12 INDIA COMMUNITY ACQUIRED PNEUMONIA DRUGS MARKET, BY MODE OF PURCHASE 2022-2031 (USD MILLION) 77
• TABLE 13 INDIA COMMUNITY ACQUIRED PNEUMONIA DRUGS MARKET, BY TYPE, 2022-2031 (USD MILLION) 82
• TABLE 14 INDIA COMMUNITY ACQUIRED PNEUMONIA DRUGS MARKET, BY POPULATION TYPE, 2022-2031 (USD MILLION) 87
• TABLE 15 INDIA COMMUNITY ACQUIRED PNEUMONIA DRUGS MARKET, BY END USER, 2022-2031 (USD MILLION) 92
• TABLE 16 INDIA COMMUNITY ACQUIRED PNEUMONIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 97

LIST OF FIGURES

• FIGURE 1 INDIA COMMUNITY ACQUIRED PNEUMONIA DRUGS MARKET: SEGMENTATION 16
• FIGURE 2 INDIA COMMUNITY ACQUIRED PNEUMONIA DRUGS MARKET: DATA TRIANGULATION 18
• FIGURE 3 INDIA COMMUNITY ACQUIRED PNEUMONIA DRUGS MARKET: DROC ANALYSIS 19
• FIGURE 4 INDIA COMMUNITY ACQUIRED PNEUMONIA DRUGS MARKET: COUNTRYWISE MARKET ANALYSIS 20
• FIGURE 5 INDIA COMMUNITY ACQUIRED PNEUMONIA DRUGS MARKET: COMPANY RESEARCH ANALYSIS 20
• FIGURE 6 INDIA COMMUNITY ACQUIRED PNEUMONIA DRUGS MARKET: INTERVIEW DEMOGRAPHICS 21
• FIGURE 7 INDIA COMMUNITY ACQUIRED PNEUMONIA DRUGS MARKET: MARKET END USER COVERAGE GRID 23
• FIGURE 8 INDIA COMMUNITY ACQUIRED PNEUMONIA DRUGS MARKET: DBMR MARKET POSITION GRID 24
• FIGURE 9 INDIA COMMUNITY ACQUIRED PNEUMONIA DRUGS MARKET: VENDOR SHARE ANALYSIS 25
• FIGURE 10 INDIA COMMUNITY ACQUIRED PNEUMONIA DRUGS MARKET: SEGMENTATION 29
• FIGURE 11 RISING PREVALENCE OF PNEUMONIA IS DRIVING THE GROWTH OF THE INDIA COMMUNITY ACQUIRED PNEUMONIA DRUGS MARKET FROM 2024 TO 2034 30
• FIGURE 12 MACROLIDES SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE INDIA COMMUNITY ACQUIRED PNEUMONIA DRUGS MARKET IN 2024 TO 2031 30
• FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF GLOBAL RAPID DIAGNOSTIC TESTS (RTD) MARKET 36
• FIGURE 14 INDIA COMMUNITY ACQUIRED PNEUMONIA DRUGS MARKET: BY PRODUCT, 2023 47
• FIGURE 15 INDIA COMMUNITY ACQUIRED PNEUMONIA DRUGS MARKET: BY PRODUCT, 2024-2031 (USD MILLION) 48
• FIGURE 16 INDIA COMMUNITY ACQUIRED PNEUMONIA DRUGS MARKET: BY PRODUCT, CAGR (2024-2031) 48
• FIGURE 17 INDIA COMMUNITY ACQUIRED PNEUMONIA DRUGS MARKET: BY PRODUCT, LIFELINE CURVE 49
• FIGURE 18 INDIA COMMUNITY ACQUIRED PNEUMONIA DRUGS MARKET: BY ROUTE OF ADMINISTRATION, 2023 59
• FIGURE 19 INDIA COMMUNITY ACQUIRED PNEUMONIA DRUGS MARKET: BY ROUTE OF ADMINISTRATION, 2024-2031 (USD MILLION) 60
• FIGURE 20 INDIA COMMUNITY ACQUIRED PNEUMONIA DRUGS MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2024-2031) 60
• FIGURE 21 INDIA COMMUNITY ACQUIRED PNEUMONIA DRUGS MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE 61
• FIGURE 22 INDIA COMMUNITY ACQUIRED PNEUMONIA DRUGS MARKET: BY DOSAGE, 2023 64
• FIGURE 23 INDIA COMMUNITY ACQUIRED PNEUMONIA DRUGS MARKET: BY DOSAGE, 2024-2031 (USD MILLION) 65
• FIGURE 24 INDIA COMMUNITY ACQUIRED PNEUMONIA DRUGS MARKET: BY DOSAGE, CAGR (2024-2031) 65
• FIGURE 25 INDIA COMMUNITY ACQUIRED PNEUMONIA DRUGS MARKET: BY DOSAGE, LIFELINE CURVE 66
• FIGURE 26 INDIA COMMUNITY ACQUIRED PNEUMONIA DRUGS MARKET: BY PRODUCT TYPE, 2023 69
• FIGURE 27 INDIA COMMUNITY ACQUIRED PNEUMONIA DRUGS MARKET: BY PRODUCT TYPE, 2024-2031 (USD MILLION) 70
• FIGURE 28 INDIA COMMUNITY ACQUIRED PNEUMONIA DRUGS MARKET: BY PRODUCT TYPE, CAGR (2024-2031) 70
• FIGURE 29 INDIA COMMUNITY ACQUIRED PNEUMONIA DRUGS MARKET: BY PRODUCT TYPE, LIFELINE CURVE 71
• FIGURE 30 INDIA COMMUNITY ACQUIRED PNEUMONIA DRUGS MARKET: BY MODE OF PURCHASE, 2023 74
• FIGURE 31 INDIA COMMUNITY ACQUIRED PNEUMONIA DRUGS MARKET: BY MODE OF PURCHASE, 2024-2031 (USD MILLION) 75
• FIGURE 32 INDIA COMMUNITY ACQUIRED PNEUMONIA DRUGS MARKET: BY MODE OF PURCHASE, CAGR (2024-2031) 75
• FIGURE 33 INDIA COMMUNITY ACQUIRED PNEUMONIA DRUGS MARKET: BY MODE OF PURCHASE, LIFELINE CURVE 76
• FIGURE 34 INDIA COMMUNITY ACQUIRED PNEUMONIA DRUGS MARKET: BY TYPE, 2023 79
• FIGURE 35 INDIA COMMUNITY ACQUIRED PNEUMONIA DRUGS MARKET: BY TYPE, 2024-2031 (USD MILLION) 80
• FIGURE 36 INDIA COMMUNITY ACQUIRED PNEUMONIA DRUGS MARKET: BY TYPE, CAGR (2024-2031) 80
• FIGURE 37 INDIA COMMUNITY ACQUIRED PNEUMONIA DRUGS MARKET: BY TYPE, LIFELINE CURVE 81
• FIGURE 38 INDIA COMMUNITY ACQUIRED PNEUMONIA DRUGS MARKET: BY POPULATION TYPE, 2023 84
• FIGURE 39 INDIA COMMUNITY ACQUIRED PNEUMONIA DRUGS MARKET: BY POPULATION TYPE, 2024-2031 (USD MILLION) 85
• FIGURE 40 INDIA COMMUNITY ACQUIRED PNEUMONIA DRUGS MARKET: BY POPULATION TYPE, CAGR (2024-2031) 85
• FIGURE 41 INDIA COMMUNITY ACQUIRED PNEUMONIA DRUGS MARKET: BY POPULATION TYPE, LIFELINE CURVE 86
• FIGURE 42 INDIA COMMUNITY ACQUIRED PNEUMONIA DRUGS MARKET: BY END USER, 2023 89
• FIGURE 43 INDIA COMMUNITY ACQUIRED PNEUMONIA DRUGS MARKET: BY END USER, 2024-2031 (USD MILLION) 90
• FIGURE 44 INDIA COMMUNITY ACQUIRED PNEUMONIA DRUGS MARKET: BY END USER, CAGR (2024-2031) 90
• FIGURE 45 INDIA COMMUNITY ACQUIRED PNEUMONIA DRUGS MARKET: BY END USER, LIFELINE CURVE 91
• FIGURE 46 INDIA COMMUNITY ACQUIRED PNEUMONIA DRUGS MARKET: BY DISTRIBUTION CHANNEL, 2023 94
• FIGURE 47 INDIA COMMUNITY ACQUIRED PNEUMONIA DRUGS MARKET: BY DISTRIBUTION CHANNEL, 2024-2031 (USD MILLION) 95
• FIGURE 48 INDIA COMMUNITY ACQUIRED PNEUMONIA DRUGS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2024-2031) 95
• FIGURE 49 INDIA COMMUNITY ACQUIRED PNEUMONIA DRUGS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE 96
• FIGURE 50 INDIA COMMUNITY ACQUIRED PNEUMONIA DRUGS MARKET: COMPANY SHARE 2023 (%) 98